• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    PMGC Holdings Inc. Signs Letter of Intent to Acquire Profitable U.S.-Based AS9100D & ISO 9001:2015 Certified CNC Machine Shop Serving Aerospace, Defense, and Industrial Markets for over 35 years

    6/16/25 8:00:00 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ELAB alert in real time by email
    • Acquisition Target Specializes in Precision Milling, Turning, Mold Manufacturing, and Specialty Metals Expertise Serving Aerospace, Defense, and Industrial Markets
    • This is PMGC's third pending acquisition since April of 2025, demonstrating that its M&A strategy is well underway, with additional deals expected this year.
    • PMGC Sees Significant Opportunity in Acquiring Additional US based CNC and Precision Manufacturing Companies Serving Aerospace, Industrial, and Defense Markets.

    NEWPORT BEACH, Calif., June 16, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:ELAB) (the "Company," "PMGC," "we," or "us"), a diversified public holding company, is pleased to announce the signing of a non-binding Letter of Intent ("LOI") to acquire a California-based, cash-flow positive computer numerical control ("CNC") machining company with over 35 years of operational history.

    About the Target Company

    The Target company ("Target") is an established CNC machining business specializing in precision milling and turning, mold manufacturing, and working with exotic metals such as titanium and Inconel. The company holds AS9100D and ISO 9001:2015 certifications—two of the most widely used international quality standards in manufacturing—commonly required by major aerospace and defense contractors and leading industrial manufacturers.

    Target serves customers across the aerospace, defense, space, commercial, and industrial sectors. Despite having no formal sales team or marketing budget, Target has developed long-standing customer relationships through repeat business and referrals, which the Company believes reflects Target's reputation for quality and trust.

    Target generated approximately $1.4 million in revenue and $215,000 in adjusted EBITDA in 2024.

    Strategic Rationale

    PMGC believes the potential acquisition of Target fits squarely within PMGC's strategy of acquiring U.S.-based, cash-flow-positive manufacturing businesses with strong fundamentals and growth potential. The Target stands out to the Company for its high-quality and longstanding customer base, advanced technical capabilities, and consistent demand across critical industries. PMGC also believes in the strategic benefit this potential acquisition may provide, given its view that recent geopolitical dynamics and supply chain vulnerabilities may accelerate a national effort to rebuilding American manufacturing capabilities. Federal legislation—including the CHIPS and Science Act and the Inflation Reduction Act—is investing funds in to promote onshoring, innovation, and industrial independence. The Company believes that manufacturers with AS9100D and ISO 9001:2015 certifications, such as the Target are well-positioned to benefit, as these credentials are often mandatory for work with Department of Defense programs, NASA contracts, and major aerospace original equipment manufacturers. The Company believes that demand for qualified U.S.-based suppliers is rising as defense and industrial clients prioritize secure, high-quality, domestic partners.

    "This acquisition reflects our continued commitment to acquiring specialized, resilient businesses that operate at the highest standards," said Graydon Bensler, Chief Executive Officer of PMGC Holdings Inc. "With its reliable certifications, niche capabilities in specialty metals, and trusted relationships across critical industries, this company adds both operational depth and strategic relevance to our portfolio."

    The closing of this anticipated acquisition is subject to customary conditions, including completion of due diligence, certain corporate approvals, and execution and delivery of definitive documentation. We cannot assure that closing of the acquisition will occur.

    About PMGC Holdings Inc.

    PMGC Holdings Inc. is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries. Currently, our portfolio consists of three wholly owned subsidiaries: Northstrive Biosciences Inc., PMGC Research Inc., and PMGC Capital LLC. We are committed to exploring opportunities in multiple sectors to maximize growth and value. For more information, please visit https://www.pmgcholdings.com.

    Forward-Looking Statements

    Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "believes," "expects," "plans," "potential," "would" and "future" or similar expressions such as "look forward" are intended to identify forward-looking statements. Forward-looking statements are made as of the date of this press release and are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results. Therefore, you should not rely on any of these forward-looking statements. These and other risks are described more fully in PMGC Holdings' filings with the United States Securities and Exchange Commission ("SEC"), including the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 28, 2025, and its other documents subsequently filed with or furnished to the SEC. Investors and security holders are urged to read these documents free of charge on the SEC's web site at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

    IR Contact:

    [email protected]



    Primary Logo

    Get the next $ELAB alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ELAB

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ELAB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • PMGC Holdings Inc. Completes Acquisition of Custom IT Packaging Company Pacific Sun Packaging with Over $2,000,000 in Combined Revenue for Fiscal Years 2023 and 2024

      Serves over 300 Commercial Clients including Data Centers, Technology Manufacturers and Information Technology (IT) Service Providers.Adds cash flow positive revenue, enhances PMGC's exposure to U.S. semiconductor and artificial intelligence ("AI") infrastructure growth, and marks the launch of its strategic acquisition program targeting U.S. businesses. NEWPORT BEACH, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:ELAB) (the "Company," "PMGC," "we," or "us"), a diversified public holding company, today announced that it has completed the acquisition of Pacific Sun Packaging Inc. ("Pacific Sun") a specialized custom IT packaging company based in San Clemente, Califor

      7/10/25 8:30:00 AM ET
      $ELAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PMGC Holdings Inc. Signs Non-Binding LOI to Acquire CNC Aerospace Manufacturer Generating $4.5 Million in Annual Revenue

      Serves Multiple Tier-1 Aerospace Clients AS9100 and ISO 9001-Certified CNC Manufacturer NEWPORT BEACH, Calif., June 24, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:ELAB) (the "Company," "PMGC," "we," or "us"), a diversified public holding company, today announced that it has entered into a non-binding Letter of Intent ("LOI") to acquire a U.S.-based, CNC machining company specializing in manufacturing high-complexity components for the aerospace and defense sectors. About the Target Company The target company, founded in 1948 is AS9100 and ISO 9001certified CNC machining firm specializing in precision aerospace components. With over 75 years of experience, the company ope

      6/24/25 8:30:00 AM ET
      $ELAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PMGC Capital LLC Urges Alaunos Therapeutics (NASDAQ: TCRT) to Accept Term Sheet from Leading Wall Street Bank Behind Many Leading Crypto Strategies

      NEWPORT BEACH, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- PMGC Capital LLC ("PMGC Capital"), a wholly owned subsidiary of PMGC Holdings Inc. (NASDAQ:ELAB), today issued a public statement urging Alaunos Therapeutics, Inc. (NASDAQ:TCRT) to accept and act upon the term sheet previously facilitated through a leading Wall Street Bank. As disclosed in PMGC Capital's May 14, 2025 press release, available on the PMGC Holdings website, PMGC Capital holds a significant ownership position in Alaunos and continues to act in the best interest of all shareholders. The proposed financing sent to the board on 5/25/2025, introduced by PMGC Capital and led by a leading wall street bank, represents a compe

      6/18/25 9:52:27 AM ET
      $ELAB
      $TCRT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO & CFO Bensler Graydon was granted 3,036,437 units of Series B Preferred Stock (SEC Form 4)

      4 - PMGC Holdings Inc. (0001840563) (Issuer)

      3/28/25 9:52:32 PM ET
      $ELAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: New insider Bensler Graydon claimed ownership of 983,120 shares (SEC Form 3)

      3/A - PMGC Holdings Inc. (0001840563) (Issuer)

      3/28/25 9:51:28 PM ET
      $ELAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Braeden Lichti was granted 3,336,437 units of Series B Preferred Stock (SEC Form 4)

      4 - PMGC Holdings Inc. (0001840563) (Issuer)

      3/28/25 9:47:45 PM ET
      $ELAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELAB
    Financials

    Live finance-specific insights

    See more
    • PMGC Holdings Inc. Completes Acquisition of Custom IT Packaging Company Pacific Sun Packaging with Over $2,000,000 in Combined Revenue for Fiscal Years 2023 and 2024

      Serves over 300 Commercial Clients including Data Centers, Technology Manufacturers and Information Technology (IT) Service Providers.Adds cash flow positive revenue, enhances PMGC's exposure to U.S. semiconductor and artificial intelligence ("AI") infrastructure growth, and marks the launch of its strategic acquisition program targeting U.S. businesses. NEWPORT BEACH, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:ELAB) (the "Company," "PMGC," "we," or "us"), a diversified public holding company, today announced that it has completed the acquisition of Pacific Sun Packaging Inc. ("Pacific Sun") a specialized custom IT packaging company based in San Clemente, Califor

      7/10/25 8:30:00 AM ET
      $ELAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments

      Agreement adds two drug candidates to product pipeline consisting of (i) "EL-22", a clinical stage engineered probiotic expressing myostatin, and (ii) "EL-32", a preclinical engineered probiotic expressing dual myostatin & activin-A.Exclusive license covers global rights excluding South Korea.Clinical and preclinical data supports advancing EL-22, a novel investigational myostatin asset for the treatment of obesity for an investigational new drug "IND" application in 2025. EL-22 has demonstrated significant increase in body weight and restored muscle damage in preclinical mouse models, suggesting potential as a combination to glucagon-like peptide-1 "GLP-1" products to treat obesity. NEWPOR

      5/1/24 9:00:00 AM ET
      $ELAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELAB
    Leadership Updates

    Live Leadership Updates

    See more
    • PMGC Holdings Inc. Expands Investment & M&A Efforts, Actively Seeking Acquisitions and Investments Through Strategic Sponsorship of TCA Venture Group

      NEWPORT BEACH, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (the "Company" or "PMGC," "our," or "we") (NASDAQ:ELAB), a diversified holding company, is proud to announce its annual sponsorship of TCA Venture Group's ("TCA") Orange County network for 2025. As a Southern California Network Sponsor, PMGC is actively pursuing investments and M&A opportunities to strengthen its portfolio while fostering local business growth and expanding its market presence. TCA Venture Group (formerly known as Tech Coast Angels) is one of the largest and most active angel investor networks in the United States. With a history spanning over 25 years, TCA has been instrumental in funding early-s

      2/27/25 8:00:00 AM ET
      $ELAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elevai Labs Inc. Subsidiary, Elevai Biosciences, Continues to Advance its Scientific Advisory Board with the Appointment of Orian Shirihai, MD, PhD

      Professor of Medicine at the University of California, Los Angeles (UCLA), where he serves as Director of the UCLA Metabolism Research Theme.Over 180 publications in the field of obesity & metabolism, along with multiple NIH-funded projects as Principal Investigator.Dr. Shirihai is a renowned researcher regularly invited as a keynote speaker at annual scientific conferences and has consulted for Johnson & Johnson, Bayer, AstraZeneca and Pfizer, among other healthcare companies. NEWPORT BEACH, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ:ELAB) ("Elevai" or the "Company"), a pioneering force in medical aesthetics, announced the appointment of Orian Shirihai, MD, PhD, t

      7/30/24 9:00:26 AM ET
      $ELAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elevai Labs Forms New Scientific Advisory Board for its Weight Loss Programs

      NEWPORT BEACH, Calif., June 14, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ:ELAB) ("Elevai" or the "Company"), a pioneering force in medical aesthetics, announced the formation of a new Scientific Advisory Board to support the advancement of EL-22, a first-in-class engineered probiotic approach, to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. "We are honored to be forming a Scientific Advisory Board with renowned members that possess deep and complementary knowledge in metabolic diseases, obesity, weight management, muscle preservation and physical function in addition to significant experience in clinical

      6/14/24 9:00:00 AM ET
      $ELAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Elevai Labs Inc.

      SC 13G - Elevai Labs Inc. (0001840563) (Subject)

      11/14/24 5:53:26 PM ET
      $ELAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Elevai Labs Inc.

      SC 13G - Elevai Labs Inc. (0001840563) (Subject)

      10/2/24 4:01:03 PM ET
      $ELAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Elevai Labs Inc.

      SC 13G - Elevai Labs Inc. (0001840563) (Subject)

      10/1/24 4:01:02 PM ET
      $ELAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELAB
    SEC Filings

    See more
    • PMGC Holdings Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Other Events, Financial Statements and Exhibits

      8-K - PMGC Holdings Inc. (0001840563) (Filer)

      7/11/25 5:06:12 PM ET
      $ELAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PMGC Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - PMGC Holdings Inc. (0001840563) (Filer)

      6/24/25 11:38:43 AM ET
      $ELAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PMGC Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - PMGC Holdings Inc. (0001840563) (Filer)

      6/9/25 2:03:11 PM ET
      $ELAB
      Biotechnology: Pharmaceutical Preparations
      Health Care